Global Peptide Therapeutics Market Report and Forecast 2023-2031

Abstract
Global Peptide Therapeutics Market Report and Forecast 2023-2031
Global Peptide Therapeutics Market Outlook:
The global peptide therapeutics market value was USD 36.1 billion in 2022, driven by the rising advancements in peptide synthesis technologies across the globe. The market size is anticipated to grow at a CAGR of 7.6% during the forecast period of 2023-2031 to achieve a value of USD 69.9 billion by 2031.

Peptide Therapeutics: Introduction
Peptide therapeutics are a class of drugs composed of short chains of amino acids, known as peptides. Peptides play a crucial role in various biological processes and can be engineered to target specific disease pathways or cellular receptors. They offer a promising approach to treating a wide range of diseases, including cancer, diabetes, cardiovascular disorders, and infectious diseases.
Peptide therapeutics possess several advantages over traditional small molecule drugs. They are highly specific and have lower off-target effects, leading to reduced side effects and improved safety profiles. Peptides can be designed to mimic natural signaling molecules in the body, allowing for targeted interactions with specific cellular receptors or enzymes. Additionally, peptides can be easily synthesized, modified, and optimized for enhanced stability, bioavailability, and pharmacokinetics.

Key Trends in the Peptide Therapeutics Market
Some key trends in the peptide therapeutics market are:
•Increased focus on peptide-based cancer therapies: Peptide therapeutics have shown promising potential in cancer treatment, particularly in targeted therapies and immunotherapies. There is a growing trend towards the development of peptide-based cancer drugs that can selectively target cancer cells, inhibit tumor growth, and enhance the body's immune response against cancer.
•Advancements in peptide synthesis and modification technologies: The development of innovative peptide synthesis techniques, such as solid-phase peptide synthesis (SPPS) and recombinant DNA technology, has facilitated the production of complex and modified peptides with enhanced stability and bioavailability. These advancements have expanded the possibilities for peptide drug design and optimization.
•Rise of peptide-based vaccines: Peptides are being explored as vaccine candidates for various infectious diseases and therapeutic indications. Peptide-based vaccines offer advantages such as improved safety profiles, targeted immune responses, and the ability to elicit specific immune reactions against disease-causing pathogens or antigens.

Peptide Therapeutics Market Segmentations

Market Breakup by Type
•Branded Peptide
•Generics Peptide

Market Breakup by Applications
•Cancer, Cardiovascular Disease
•Metabolic Disease
•Respiratory Disease
•Infectious Disease
•Others

Market Breakup by Route of Administration
•Oral
Tablets
Capsules
•Parenteral
Intravascular
Intramuscular
Market Breakup by Type of Manufactures
•In House
•Outsourced

Market Breakup by Distribution Channels
•Hospitals Pharmacies
•Retail Pharmacies
•Online Pharmacies
•Others

Market Breakup by Region

•North America
United States of America
Canada
•Europe
United Kingdom
Germany
France
Italy
Others
•Asia Pacific
China
Japan
India
ASEAN
Australia
Others
•Latin America
Brazil
Argentina
Mexico
Others
•Middle East and Africa
Saudi Arabia
United Arab Emirates
Nigeria
South Africa
Others

Peptide Therapeutics Market Scenario

The market for peptide therapeutics has experienced significant growth in recent years and is expected to continue expanding in the coming years. Peptide therapeutics offer unique advantages in terms of targeted therapy, reduced side effects, and improved safety profiles, making them attractive options for treating various diseases.
The market for peptide therapeutics is driven by factors such as the increasing prevalence of chronic diseases, advancements in peptide synthesis technologies, and the growing understanding of disease mechanisms at the molecular level. Pharmaceutical companies are investing in research and development to discover and develop novel peptide-based drugs with improved efficacy and reduced toxicity.
In summary, peptide therapeutics represent a promising avenue for the treatment of various diseases. They offer targeted and specific interactions with cellular receptors, reduced side effects, and improved safety profiles. The market for peptide therapeutics is driven by the increasing prevalence of chronic diseases, advancements in peptide synthesis technologies, and growing investments in research and development. With ongoing innovation and regulatory support, peptide therapeutics are poised to make significant contributions to the future of medicine.
Peptide Therapeutics Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
•F. Hoffmann-La Roche Ltd.
•GlaxoSmithKline plc.
•Novartis AG
•Pfizer, Inc.
•Sanofi
•Takeda Pharmaceutical Company Limited
•Teva Pharmaceutical Industries Ltd
•Ipsen Pharma
•AstraZeneca
•Lonza
•Merck Sharp & Dohme Corp.
•Novo Nordisk A/S
•PolyPeptide Group
•CordenPharma International

Content
Table of Contents

1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Peptide Therapeutics Market Overview
3.1 Global Peptide Therapeutics Market Historical Value (2016-2022)
3.2 Global Peptide Therapeutics Market Forecast Value (2023-2031)
4 Global Peptide Therapeutics Market Landscape
4.1 Global Peptide Therapeutics Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Peptide Therapeutics Product Landscape
4.2.1 Analysis by Type
4.2.2 Analysis by Distribution Channel
4.2.3 Analysis by Applications
5 Global Peptide Therapeutics Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter’s Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Peptide Therapeutics Market Segmentation
6.1 Global Peptide Therapeutics Market by Type
6.1.1 Market Overview
6.1.2 Branded Peptide
6.1.3 Generics Peptide
6.2 Global Peptide Therapeutics Market by Applications
6.2.1 Market Overview
6.2.2 Cancer, Cardiovascular Disease
6.2.3 Metabolic Disease
6.2.4 Respiratory Disease
6.2.5 Infectious Disease
6.2.6 Others
6.3 Global Peptide Therapeutics Market by Route of Administration
6.3.1 Market Overview
6.3.2 Oral
6.3.2.1 Tablets
6.3.2.2 Capsules
6.3.3 Parenteral
6.3.3.1 Intravascular
6.3.3.2 intramuscular
6.4 Global Peptide Therapeutics Market by Type of Manufactures
6.4.1 Market Overview
6.4.2 In House
6.4.3 Outsourced
6.5 Global Peptide Therapeutics Market by Distribution Channels
6.5.1 Market Overview
6.5.2 Hospitals Pharmacies
6.5.3 Retail Pharmacies
6.5.4 Online Pharmacies
6.5.5 Others
6.6 Global Peptide Therapeutics Market by Region
6.6.1 Market Overview
6.6.2 North America
6.6.3 Europe
6.6.4 Asia Pacific
6.6.5 Latin America
6.6.6 Middle East and Africa
7 North America Peptide Therapeutics Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe Peptide Therapeutics Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific Peptide Therapeutics Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.5 ASEAN
9.6 Australia
9.7 Others
10 Latin America Peptide Therapeutics Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa Peptide Therapeutics Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Patent Analysis
12.1 Analysis by Type of Patent
12.2 Analysis by Publication year
12.3 Analysis by Issuing Authority
12.4 Analysis by Patent Age
12.5 Analysis by CPC Analysis
12.6 Analysis by Patent Valuation
12.7 Analysis by Key Players
13 Grants Analysis
13.1 Analysis by year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by NIH Departments
13.7 Analysis by Recipient Organization
14 Clinical Trials Analysis
14.1 Analysis by Trial Registration Year
14.2 Analysis by Trial Status
14.3 Analysis by Trial Phase
14.4 Analysis by Therapeutic Area
14.5 Analysis by Geography
15 Funding Analysis
15.1 Analysis by Funding Instances
15.2 Analysis by Type of Funding
15.3 Analysis by Funding Amount
15.4 Analysis by Leading Players
15.5 Analysis by Leading Investors
15.6 Analysis by Geography
16 Partnership and Collaborations Analysis
16.1 Analysis by Partnership Instances
16.2 Analysis by Type of Partnership
16.3 Analysis by Leading Players
16.4 Analysis by Geography
17 Regulatory Framework
17.1 Regulatory Overview
17.1.1 US FDA
17.1.2 EU EMA
17.1.3 INDIA CDSCO
17.1.4 JAPAN PMDA
17.1.5 Others
18 Supplier Landscape
18.1 F. Hoffmann-La Roche Ltd.
18.1.1 Financial Analysis
18.1.2 Product Portfolio
18.1.3 Demographic Reach and Achievements
18.1.4 Mergers and Acquisitions
18.1.5 Certifications
18.2 GlaxoSmithKline plc.
18.2.1 Financial Analysis
18.2.2 Product Portfolio
18.2.3 Demographic Reach and Achievements
18.2.4 Mergers and Acquisitions
18.2.5 Certifications
18.3 Novartis AG
18.3.1 Financial Analysis
18.3.2 Product Portfolio
18.3.3 Demographic Reach and Achievements
18.3.4 Mergers and Acquisitions
18.3.5 Certifications
18.4 Pfizer, Inc.
18.4.1 Financial Analysis
18.4.2 Product Portfolio
18.4.3 Demographic Reach and Achievements
18.4.4 Mergers and Acquisitions
18.4.5 Certifications
18.5 Sanofi
18.5.1 Financial Analysis
18.5.2 Product Portfolio
18.5.3 Demographic Reach and Achievements
18.5.4 Mergers and Acquisitions
18.5.5 Certifications
18.6 Takeda Pharmaceutical Company Limited
18.6.1 Financial Analysis
18.6.2 Product Portfolio
18.6.3 Demographic Reach and Achievements
18.6.4 Mergers and Acquisitions
18.6.5 Certifications
18.7 Teva Pharmaceutical Industries Ltd
18.7.1 Financial Analysis
18.7.2 Product Portfolio
18.7.3 Demographic Reach and Achievements
18.7.4 Mergers and Acquisitions
18.7.5 Certifications
18.8 Ipsen Pharma
18.8.1 Financial Analysis
18.8.2 Product Portfolio
18.8.3 Demographic Reach and Achievements
18.8.4 Mergers and Acquisitions
18.8.5 Certifications
18.9 AstraZeneca
18.9.1 Financial Analysis
18.9.2 Product Portfolio
18.9.3 Demographic Reach and Achievements
18.9.4 Mergers and Acquisitions
18.9.5 Certifications
18.10 Lonza
18.10.1 Financial Analysis
18.10.2 Product Portfolio
18.10.3 Demographic Reach and Achievements
18.10.4 Mergers and Acquisitions
18.10.5 Certifications
18.11 Merck Sharp & Dohme Corp.
18.11.1 Financial Analysis
18.11.2 Product Portfolio
18.11.3 Demographic Reach and Achievements
18.11.4 Mergers and Acquisitions
18.11.5 Certifications
18.12 Novo Nordisk A/S
18.12.1 Financial Analysis
18.12.2 Product Portfolio
18.12.3 Demographic Reach and Achievements
18.12.4 Mergers and Acquisitions
18.12.5 Certifications
18.13 PolyPeptide Group
18.13.1 Financial Analysis
18.13.2 Product Portfolio
18.13.3 Demographic Reach and Achievements
18.13.4 Mergers and Acquisitions
18.13.5 Certifications
18.14 CordenPharma International
18.14.1 Financial Analysis
18.14.2 Product Portfolio
18.14.3 Demographic Reach and Achievements
18.14.4 Mergers and Acquisitions
18.14.5 Certifications
19 Global Peptide Therapeutics Distribution Model (Additional Insight)
19.1 Overview
19.2 Potential Distributors
19.3 Key Parameters for Distribution Partner Assessment
20 Key Opinion Leaders (KOL) Insights (Additional Insight)
21 Company Competitiveness Analysis (Additional Insight)
21.1 Very Small Companies
21.2 Small Companies
21.3 Mid-Sized Companies
21.4 Large Companies
21.5 Very Large Companies
22 Payment Methods (Additional Insight)
22.1 Government Funded
22.2 Private Insurance
22.3 Out-of-Pocket